Clervonafusp Biosimilar di-Fab Fusion Protein (SLC29A2/ENT2) for Research

Cat No.: GMP-Bios-ab-111

Pre-Made Clervonafusp biosimilar, di-Fab Fusion, Anti-SLC29A2/ENT2 Antibody: Anti-DER12/HNP36 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-111-1mg 1mg
GMP-Bios-ab-111-10mg 10mg
GMP-Bios-ab-111-100mg 100mg
GMP-Bios-ab-111-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Clervonafusp biosimilar, di-Fab Fusion, Anti-SLC29A2/ENT2 Antibody: Anti-DER12/HNP36 therapeutic antibody
INN Name Clervonafusp
TargetSLC29A2
Formatdi-Fab Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesValerion Therapeutics
Conditions Approvedna
Conditions ActiveGlycogen storage disease type II
Conditions Discontinuedna
Development Techna



About target - SLC29A2

1. Protein Equilibrative nucleoside transporter 2

2. Gene SLC29A2

3. Organism Homo sapiens (Human)

Function
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.

Kinetics
Vmax for adenosine uptake is about the same for SLC29A1 and SLC29A2.
KM=0.2 mM for uridine
KM=0.75 mM for adenosinebr>